A phase I clinical trial of dextromethorphan in intractable partial epilepsy

Methods and Findings in Experimental and Clinical Pharmacology

Volumn 21, Issue 10, 1999, Pages 673-678

  Kimiskidis, V K ^a   Mirtsou Fidani, V ^a   Papaioannidou, P G ^a   Niopas, I ^a   Georgiadis, G ^a   Constadinidis, T C ^a   Kazis, A D ^a  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

Author keywords

Clinical trial; Dextromethorphan; Dextrorphan; Epilepsy; NMDA receptors

Indexed keywords

CARBAMAZEPINE; DEXTROMETHORPHAN; PHENYTOIN; VALPROIC ACID;

ANTICONVULSANT ACTIVITY; ANTICONVULSANT THERAPY; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DROWSINESS; DRUG BLOOD LEVEL; DRUG EFFICACY; FEMALE; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; INTRACTABLE EPILEPSY; MALE; PHASE 1 CLINICAL TRIAL; VERTIGO;

EID: 0033399382     PISSN: 03790355     EISSN: None     Source Type: Journal    
DOI: 10.1358/mf.1999.21.10.795765     Document Type: Article

References (22)

1. Rogawski, M.A. The NMDA receptor, NMDA antagonists and epilepsy therapy. A status report. Drugs 1992, 44(3): 279-92.
2. Troupin, A.S., Mendins, J.R., Cheug, F. et al. MK-801. In: New Anticonvulsant Drugs. Medrum, B.S., Porter. R.J. (Eds.). J. Libbey: London 1986, 191-201.
3. Sveinbjornsdottir, S., Sander, J.W.A., Simpson, A. et al. First experience with the NMDA antagonist D-CPP-ene (SDZ EAA-494) in patients with epilepsy. Epilepsia 1993, 34(Suppl. 2): S91-2.
4. Trube, G., Netzer, R. Dextromethorphan: Cellular effects is reducing neuronal hyperactivity. Epilepsia 1994, 35(Suppl. 5): 562-7.
5. Fisher, R.S., Cysyk, B.J., Lesser, R.P. et al. Dextromethorphan for treatment of complex partial seizures. Neurology 1990, 40: 547-9.
6. Albers, G.W., Saenz, R.E., Moses, J.A. Jr. et al. Safety and tolerance of oral dextromethorphan in patients at risk for brain ischemia. Stroke 1991, 22(8): 1075-7.
7. Hollander, D., Pradas, J., Kaplan, R. et al. High-dose dextromethorphan in amyotrophic lateral sclerosis: Phase I safety and pharmacokinetic studies. Ann Neurol 1994, 36: 920-4.
8. Bonuccelli, U., Del Otto, P., Piccini, P. et al. Dextromethorphan and parkinsonism. Lancet 1992, 340: 53.
9. Walker, F.O., Hunt, V.P. An open label trial of dextromethorphan in Huntington's disease. Clin Neuropharmacol 1989, 12: 322-30.
10. Commission on Antiepileptic Drugs of the International League Against Epilepsy. Guidelines for clinical evaluation of antiepileptic drugs. Epilepsia 1989, 30(4): 400-8.
11. Kazis, A., Kimiskidis, V., Niopas, I. Pharmacokinetics of dextromethorphan and dextrorphan in epileptic patients. Acta Neurol Scand 1996, 93: 94-8.
12. Cramer, J.A. , Mattson, R.H. Quantitative approaches to seizure severity. In: Quantitative Assessment in Epilepsy Care. NATO ASI Series. Meinardi, H. et al. (Eds). Plenum Press: New York 1993, 55-71.
13. Mattson, R.H., Cramer, J.A. Quantitative assessment of adverse drug effects. In: Quantitative Assessment in Epilepsy Care. NATO ASI Series. Meinardi. H. et al. (Eds.). Plenum Press: New York 1993, 123-35.
14. Steinberg, G.K., Kunis, D., Dela Paz, R. et al. Neuroprotection following focal cerebral ischemia with the NMDA antagonist dextromethorphan, has a favourable dose response profile. Neurol Res 1993, 15: 174-80.
15. UK Gabapentin Study Group. Gabapentin in partial epilepsy. Lancet 1990, 335: 1114-7.
16. Wieser, H.G., Beck, H. Improvement of medically refractory temporal lobe epilepsy with dextromethorphan. J Epilepsy 1992, 5: 246-7.
17. Hamosh, A., McDonald, J.W., Valle, D. et al. Dextromethorphan and high-dose benzoate therapy for nonketotic hyperglycinemia in an infant. J Pediatr 1992, 121: 131-5.
18. Schmitt, B., Steinmann, B., Gitzelmann, R. et al. Nonketotic hyperglycinemia: Clinical and electrophysiologic effects of dextromethorphan, antagonist of the NMDA receptor. Neurology 1993, 43:421-4.
19. Schmitt, B., Netzer, R., Fanconi, S. et al, Drug refractory epilepsy in brain damage: Effect of dextromethorphan on EEG in four patients. J Neurol Neurosurg Psychiatry 1994, 57: 333-9.
20. Loscher, W., Honack, D. Differences in anticonvulsant potency and adverse effects between dextromethorphan and dextrorphan in amygdala-kindled and non-kindled rats. Kur J Pharmacol 1993, 238: 191-200.
21. Thomson, K.W., Wasterlain, C.G. Dextromethorphan (letter). Neurology 1994, 44: 583.
22. Spilker, B., Segreli, A. Validation of the phenomenon of regression of seizure frequency in epilepsy. Epilepsia 1984, 25(4): 443-9.